7741:TSEHOYA CORPORATION Analysis
Data as of 2026-06-06 - not real-time
MX$3,028.62
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
HOYA Corp is trading exactly at its 20‑day SMA of 3,028 MXN, well above the 50‑day (2,584 MXN) and 200‑day (2,321 MXN) averages, indicating a short‑term bullish bias. However, the RSI is at a full 100, flagging extreme overbought conditions, while the MACD histogram is negative and the MACD line sits below its signal, suggesting bearish momentum may be gathering. Volatility is unusually high at 88% over the past 30 days, and the market sentiment index reads “Extreme Greed,” which together point to a potentially fragile rally.
On the fundamentals side, HOYA posted 14% revenue growth, robust gross (55%) and operating (47%) margins, and a strong ROE of 25%, underscoring solid profitability. The balance sheet is cash‑rich (cash > 10× debt) and the dividend yield of 1.09% is supported by a modest payout ratio of ~40%. A discounted cash‑flow model values the company at roughly 14,060 MXN, far above the current price, yet the trailing P/E of 37.7 versus an industry average of 27.9 signals a price premium that may be hard to justify on earnings alone.
On the fundamentals side, HOYA posted 14% revenue growth, robust gross (55%) and operating (47%) margins, and a strong ROE of 25%, underscoring solid profitability. The balance sheet is cash‑rich (cash > 10× debt) and the dividend yield of 1.09% is supported by a modest payout ratio of ~40%. A discounted cash‑flow model values the company at roughly 14,060 MXN, far above the current price, yet the trailing P/E of 37.7 versus an industry average of 27.9 signals a price premium that may be hard to justify on earnings alone.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- RSI at 100 indicating overbought conditions
- Bearish MACD histogram suggesting near‑term downside
- High 30‑day volatility could trigger sharp corrections
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value far exceeds market price
- Strong revenue growth and high operating margins
- Healthy cash position and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Consistent high ROE and profit margins
- Low net debt and ample cash reserves
- Growth opportunities in medical devices and optical technologies
Key Metrics & Analysis
Financial Health
Revenue Growth14.20%
Profit Margin26.70%
P/E Ratio37.7
ROE25.06%
ROA15.51%
Debt/Equity4.08
P/B Ratio9.1
Op. Cash FlowMX$278.4B
Free Cash FlowMX$174.9B
Industry P/E27.9
Technical Analysis
TrendBullish
RSI100.0
SupportMX$3,028.62
ResistanceMX$3,028.62
MA 20MX$3,028.62
MA 50MX$2,583.52
MA 200MX$2,321.22
MACDBearish
VolumeStable
Fear & Greed Index83.02
Valuation
Fair ValueMX$14,060.72
GradeUndervalued
TypeGrowth
Dividend Yield1.09%
Risk Assessment
Beta-0.10
Volatility88.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.